Highlight of 2023: Unlocking the therapeutic potential of natural killer cells—advances in adaptive functions, cellular engineering and immunotherapy

IF 3.2 4区医学 Q3 CELL BIOLOGY

Immunology & Cell Biology Pub Date : 2024-05-02 DOI:10.1111/imcb.12769

Pui Yeng Lam, Fernando Souza-Fonseca-Guimaraes

引用次数: 0

Abstract

Natural killer (NK) cells possess potent cytotoxicity against infected and cancerous cells and hold promise in the development of new immunotherapies. This article for the Highlights of 2023 Series focuses on current advances in NK cell biology in cancerous and infectious settings and highlights opportunities for therapeutic interventions, including engineered NK cell therapies and advancements in feeder cell technologies.

Abstract Image

查看原文本刊更多论文

2023 年的亮点：挖掘自然杀伤细胞的治疗潜力--适应性功能、细胞工程和免疫疗法方面的进展。

自然杀伤（NK）细胞对感染细胞和癌细胞具有强大的细胞毒性，有望开发出新的免疫疗法。这篇为《2023 年亮点》系列撰写的文章重点介绍了癌症和感染性环境中 NK 细胞生物学的最新进展，并强调了治疗干预的机会，包括工程 NK 细胞疗法和饲养细胞技术的进步。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunology & Cell Biology 医学-免疫学

CiteScore

7.50

自引率

2.50%

发文量

审稿时长

4-8 weeks

期刊介绍： The Australasian Society for Immunology Incorporated (ASI) was created by the amalgamation in 1991 of the Australian Society for Immunology, formed in 1970, and the New Zealand Society for Immunology, formed in 1975. The aim of the Society is to encourage and support the discipline of immunology in the Australasian region. It is a broadly based Society, embracing clinical and experimental, cellular and molecular immunology in humans and animals. The Society provides a network for the exchange of information and for collaboration within Australia, New Zealand and overseas. ASI members have been prominent in advancing biological and medical research worldwide. We seek to encourage the study of immunology in Australia and New Zealand and are active in introducing young scientists to the discipline.